Athena Athena

X
[{"orgOrder":0,"company":"Osivax","sponsor":"European Innovation Council","pharmaFlowCategory":"D","amount":"$34.0 million","upfrontCash":"Undisclosed","newsHeadline":"Osivax Receives Over EUR 30M in Public Funding to Support Development of Universal Coronavirus & Influenza Vaccines","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"FRANCE","productType":"Vaccine","productStatus":"New Molecular Entity","date":"July 2020","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II"},{"orgOrder":0,"company":"Osivax","sponsor":"National Institute of Allergy and Infectious Diseases","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Osivax Enters Research Collaboration with the NIAID for the Evaluation of Combination Approach to Broad-Spectrum Influenza Vaccines","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"FRANCE","productType":"Vaccine","productStatus":"New Molecular Entity","date":"May 2022","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II"},{"orgOrder":0,"company":"Osivax","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Osivax Provides Clinical Development Update on Lead Influenza Vaccine Candidate OVX836","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"FRANCE","productType":"Vaccine","productStatus":"New Molecular Entity","date":"May 2022","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II"},{"orgOrder":0,"company":"Osivax","sponsor":"Bpifrance","pharmaFlowCategory":"D","amount":"$10.4 million","upfrontCash":"Undisclosed","newsHeadline":"Osivax Secures EUR 10M Grant from Bpifrance to Support Clinical Development of OVX836, a Broad-Spectrum Influenza Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"FRANCE","productType":"Vaccine","productStatus":"New Molecular Entity","date":"June 2022","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II"},{"orgOrder":0,"company":"Osivax","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Osivax Announces Clinical and Preclinical Vaccine Data Presentations at Upcoming Global Influenza Conferences","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"FRANCE","productType":"Vaccine","productStatus":"New Molecular Entity","date":"September 2022","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II"},{"orgOrder":0,"company":"Osivax","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Osivax Announces Last Patient Last Visit in Two Phase 2a Clinical Trials with Broad-Spectrum Influenza Vaccine Candidate OVX836","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"FRANCE","productType":"Vaccine","productStatus":"New Molecular Entity","date":"December 2022","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II"},{"orgOrder":0,"company":"Osivax","sponsor":"Bill & Melinda Gates Foundation","pharmaFlowCategory":"D","amount":"$1.0 million","upfrontCash":"Undisclosed","newsHeadline":"Osivax Awarded Grant from a Leading Non-Governmental Organization for OVX836, its Broad-Spectrum Influenza Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"FRANCE","productType":"Vaccine","productStatus":"New Molecular Entity","date":"March 2023","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II"},{"orgOrder":0,"company":"Osivax","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Osivax Announces Vaccination of First Participant in Phase 2a Clinical Trial Evaluating OVX836 Combined with QIVs","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"FRANCE","productType":"Vaccine","productStatus":"New Molecular Entity","date":"June 2023","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II"}]

Find Clinical Drug Pipeline Developments & Deals by Osivax

Menu
Loading...
Filters Filter
×
FILTER:
filter Company
    filter Sponsor
      filter Country
        filter Therapeutic Area
          filter Study Phase

            Active Filter(s):

            Companies By Therapeutic Area

            Development Status

            Details:

            OVX836, a first-in-class broad-spectrum influenza vaccine candidate that targets the nucleoprotein (NP), a highly conserved internal antigen, is being evaluated in combination with Quadrivalent Influenza Vaccines (QIVs).

            Lead Product(s): OVX836,Influenza Vaccine

            Therapeutic Area: Infections and Infectious Diseases Product Name: OVX836

            Highest Development Status: Phase II Product Type: Vaccine

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable June 15, 2023

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            The funding will support additional research and development of its lead, broad-spectrum influenza vaccine candidate, OVX836 that targets the nucleoprotein (NP), a highly conserved internal antigen.

            Lead Product(s): OVX836

            Therapeutic Area: Infections and Infectious Diseases Product Name: OVX836

            Highest Development Status: Phase II Product Type: Vaccine

            Partner/Sponsor/Collaborator: Bill & Melinda Gates Foundation

            Deal Size: $1.0 million Upfront Cash: Undisclosed

            Deal Type: Funding March 28, 2023

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            OVX836 targets the nucleoprotein (NP), a highly conserved internal antigen. Unlike surface antigens, NP is much less likely to mutate, providing a broader and more universal immune response.

            Lead Product(s): OVX836

            Therapeutic Area: Infections and Infectious Diseases Product Name: OVX836

            Highest Development Status: Phase II Product Type: Vaccine

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable December 21, 2022

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            OVX836, targets the nucleoprotein (NP), a highly conserved internal antigen. Unlike surface antigens, NP is much less likely to mutate, providing a broader and more universal immune response.

            Lead Product(s): OVX836,Quadrivalent Seasonal Influenza Subunit Vaccine

            Therapeutic Area: Infections and Infectious Diseases Product Name: OVX836

            Highest Development Status: Phase II Product Type: Vaccine

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable September 01, 2022

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            Osivax will apply the funds to prepare OVX836 for a Phase 2b field efficacy clinical trial to assess its efficacy against a broad range of circulating strains. OVX836 targets the nucleoprotein (NP), a highly conserved internal antigen.

            Lead Product(s): OVX836,Quadrivalent Seasonal Influenza Subunit Vaccine

            Therapeutic Area: Infections and Infectious Diseases Product Name: OVX836

            Highest Development Status: Phase II Product Type: Vaccine

            Partner/Sponsor/Collaborator: Bpifrance

            Deal Size: $10.4 million Upfront Cash: Undisclosed

            Deal Type: Funding June 23, 2022

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            OVX836 is Osivax’ T-cell based influenza candidate developed using the company’s proprietary oligoDOM® nanoparticle technology platform and designed to produce immune responses against the nucleoprotein (NP), a highly conserved internal antigen across flu strains.

            Lead Product(s): OVX836,Quadrivalent Seasonal Influenza Subunit Vaccine

            Therapeutic Area: Infections and Infectious Diseases Product Name: OVX836

            Highest Development Status: Phase II Product Type: Vaccine

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable May 25, 2022

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            Under the collaboration, NIAID will provide its self-assembling ferritin nanoparticles that serve as scaffolding to display multiple copies of HA protein, expressed on the surface of influenza viruses, to Osivax for in vivo preclinical studies in combination with OVX836.

            Lead Product(s): OVX836,Quadrivalent Seasonal Influenza Subunit Vaccine

            Therapeutic Area: Infections and Infectious Diseases Product Name: OVX836

            Highest Development Status: Phase II Product Type: Vaccine

            Partner/Sponsor/Collaborator: National Institute of Allergy and Infectious Diseases

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Collaboration May 17, 2022

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            The grant willsupport the completion of the Company’s Phase 2a immunogenicity clinical trial for OVX836, its lead universal flu vaccine candidate and the early discovery phase for its universal coronavirus vaccine program.

            Lead Product(s): OVX836

            Therapeutic Area: Infections and Infectious Diseases Product Name: OVX836

            Highest Development Status: Phase II Product Type: Vaccine

            Partner/Sponsor/Collaborator: European Innovation Council

            Deal Size: $34.0 million Upfront Cash: Undisclosed

            Deal Type: Funding July 08, 2020

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity
            Post Enquiry
            POST ENQUIRY